Imagion Biosystems has announced a notification to ineligible shareholders regarding the renounceable pro-rata offer of 28 October 2019.
Read the notification.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance